The CANTOS trial [45], which studied the effect of canakinumab, a monoclonal antibody targeting IL-1β, and studies with low-dose colchicine in CAD patients [46,47] demonstrated a reduced risk of cardiovascular events in the treatment groups, which was independent of lipid levels. This evidence concerns the gene IL1B and coronary artery disorder.